We also discovered that high expression of MYC was related to an inferior overall survival in EBV+ DLBCL patients (16 vs. 29 months, P = 0.001), but not in the EBV-negative DLBCL cohort (P > 0.05). The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.